合成路线1
该中间体在本合成路线中的序号:
(I) 3,4-Dimethoxybenzaldehyde (I) is treated with 1,3-propanedithiol (II) to give 2-(3,4-dimethoxyphenyl)-m-dithiane (III), the oxidation product of which (IV) is reacted with N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylpropanamine chloride (V) in the presence of a base.
【1】
Ramuz, H.; DE 2460593 .
|
【2】
Ramuz, H.; A new Ca2+ antagonist, Ro-111781 and its metabolites. Synthesis and physicochemical properties. Arzneim-Forsch Drug Res 1978, 28, 11, 2048.
|
【3】
Koch, H.; Ro-11,1781. Drugs Fut 1979, 4, 2, 122.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(II) |
29729 |
1,3-propanedithiol; 3-sulfanylpropylhydrosulfide
|
109-80-8 |
C3H8S2 |
详情 | 详情
|
(III) |
39515 |
2-(3,4-dimethoxyphenyl)-1,3-dithiane; 4-(1,3-dithian-2-yl)-2-methoxyphenyl methyl ether
|
|
C12H16O2S2 |
详情 |
详情
|
(IV) |
39516 |
2-(3,4-dimethoxyphenyl)-1lambda(6),3lambda(6)-dithiane-1,1,3,3-tetrone
|
|
C12H16O6S2 |
详情 |
详情
|
(V) |
29986 |
3-chloro-N-(3,4-dimethoxyphenethyl)-N-methyl-1-propanamine; N-(3-chloropropyl)-N-(3,4-dimethoxyphenethyl)-N-methylamine
|
|
C14H22ClNO2 |
详情 |
详情
|
合成路线2
该中间体在本合成路线中的序号:
(I) The synthesis of nitidine chloride was first reported in 1973. The procedure was based on the synthesis of dihydronitidine, which involves hydrocyanation of the corresponding chalcone, followed by hydrolysis, reduction and cyclization to the 2-aryl tetralone. Leukart reaction of the tetralone followed by ring closure with phosphorus oxychloride and catalytic dehydrogenation yields the benzo[c]phenanthridine nucleus. Methylation and quarternization with methyl sulfate followed by anion exchange with sodium chloride forms the chloride salt of the desired compound.
Several other syntheses of nitidine chloride have also been reported. These include: a) synthesis of the intermediates by a different route; b) photocyclization of bromobenzamide from 5-aminonaphthalene to phenanthridine; and c) condensation of homophthalic anhydride and the Schiff base to form the 3-arylisoquinoline.
Many analogues of nitidine chloride, including fagaronine. The tetramethoxy analogue, the indenoisoquinoline derivative, etc., possess significant antineoplastic activity.
【1】
Miyadera, T.; et al.; J Heterocycl Chem 1973, 10, 6, 85-88.
|
【2】
Pabbathi, V.K.; et al.; J Heterocycl Chem 1973, 10, 2, 31-33.
|
【3】
Okamoto, T.; et al.; Tetrahedron Lett 1974, 297, 2, 2269-2270.
|
【4】
Muramatsu, I.; Ahmed, M.; Ohnuki, T.; Nagatomo, T.; Futabayashi, Y.; Ishiguro, M.; J Heterocycl Chem 1981, 18, 21, 223-232.
|
【5】
Gupta, Y.K.; Sharma, M.; J Org Chem 1978, 43, 21, 286-288.
|
【6】
May, H.-J.; J Chem Soc 1959, 30, 10, 4010-4012.
|
【7】
Caldwell, J.; Glowka, F.K.; J Chem Soc - Perkins Trans I 1977, 14, 9, 2324-2328.
|
【8】
Cheng, C.C.; Zee-Chenh, R.K.-Y.; Preparation and antileukemic activity of some alkoxybenzo[c]phenanthridinium salts and corresponding dihydro derivatives. J Med Chem 1975, 18, 1, 66-71.
|
【9】
Cushman, M.; Mohan, P.; Smith, E.C.R.; Synthesis and biological activity of structural analogues of the anticancer benzophenanthridine alkaloid nitidine chloride. J Med Chem 1984, 27, 4, 544-547.
|
【10】
Zee-Cheng, R.K.-Y.; Cheng, C.C.; Nitidine Chloride. Drugs Fut 1985, 10, 2, 124.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(II) |
28953 |
1-(1,3-benzodioxol-5-yl)-1-ethanone
|
3162-29-6 |
C9H8O3 |
详情 | 详情
|
(III) |
28954 |
(E)-1-(1,3-benzodioxol-5-yl)-3-(3,4-dimethoxyphenyl)-2-propen-1-one
|
|
C18H16O5 |
详情 |
详情
|
(IV) |
28955 |
4-(1,3-benzodioxol-5-yl)-2-(3,4-dimethoxyphenyl)-4-oxobutanenitrile
|
|
C19H17NO5 |
详情 |
详情
|
(V) |
28956 |
4-(1,3-benzodioxol-5-yl)-2-(3,4-dimethoxyphenyl)-4-oxobutyric acid
|
|
C19H18O7 |
详情 |
详情
|
(VI) |
28957 |
4-(1,3-benzodioxol-5-yl)-2-(3,4-dimethoxyphenyl)butyric acid
|
|
C19H20O6 |
详情 |
详情
|
(VII) |
28958 |
6-(3,4-dimethoxyphenyl)-7,8-dihydronaphtho[2,3-d][1,3]dioxol-5(6H)-one
|
|
C19H18O5 |
详情 |
详情
|
(VIII) |
28959 |
6-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydronaphtho[2,3-d][1,3]dioxol-5-ylformamide
|
|
C20H21NO5 |
详情 |
详情
|
(IX) |
28960 |
2,3-dimethoxy-4b,5,6,11b-tetrahydro[1,3]benzodioxolo[5,6-c]phenanthridine
|
|
C20H19NO4 |
详情 |
详情
|
(X) |
28961 |
2,3-dimethoxy[1,3]benzodioxolo[5,6-c]phenanthridine
|
|
C20H15NO4 |
详情 |
详情
|
(XI) |
28962 |
2,3-dimethoxy-12-methyl[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium (sulfonatooxy)methane
|
|
C22H21NO8S |
详情 |
详情
|
合成路线3
该中间体在本合成路线中的序号:
(I) The condensation of 3,4-dimethoxybenzaldehyde (I) with glycine (II) by means of KOH in hot methanol gives racemic threo-3-(3,4-dimethoxyphenyl)serine (III), which is acylated with N-(ethoxycarbonyl)phthalimide (IV) by means of Na2CO3 in water yielding the corresponding N-phthaloyl derivative (V). The reaction of (V) with AlCl3 and ethyl mercaptan in dichloromethane affords N-phthaloyl-3-(3,4-dihydroxyphenyl)serine (VI), which is deprotected with hydrazine in refluxing ethanol to racemic threo-3-(3,4-dihydroxyphenyl)serine (VII). The resolution of the racemic form (VII) is performed through its benzyloxy derivative.
【1】
Ohashi, N.; Nagata, S.; Ishimuzi, K.; Katsube, J. (Sumitomo Pharmaceuticals Co., Ltd.); Process for the production of optically active thr. EP 0024210; US 4319040 .
|
【2】
Ohashi, N.; Nagata, S.; Ishizumi, K. (Sumitomo Pharmaceuticals Co., Ltd.); Process for producing 3-(3,4-dihydroxyphenyl)serin. EP 0128684; US 4562263 .
|
【3】
Castaner, J.; Prous, J.; L-threo-DOPS. Drugs Fut 1987, 12, 5, 433.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(II) |
20436 |
glycine
|
56-40-6 |
C2H5NO2 |
详情 | 详情
|
(III) |
22983 |
3-hydroxy-3,4-dimethoxyphenylalanine
|
|
C11H15NO5 |
详情 |
详情
|
(IV) |
10283 |
ethyl 1,3-dioxo-1,3-dihydro-2H-isoindole-2-carboxylate; N-Carbethoxyphthalimide
|
22509-74-6 |
C11H9NO4 |
详情 | 详情
|
(V) |
22985 |
3-(3,4-dimethoxyphenyl)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-hydroxypropionic acid
|
|
C19H17NO7 |
详情 |
详情
|
(VI) |
22986 |
3-(3,4-dihydroxyphenyl)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-hydroxypropionic acid
|
|
C17H13NO7 |
详情 |
详情
|
合成路线4
该中间体在本合成路线中的序号:
6-Hydroxy-2(1H)-quinolinone (I) is alkylated with epichlorohydrin in the presence of K2CO3 in MeOH to afford 6-(2,3-epoxypropoxy)-2(1H)-quinolinone (II). Ring opening of the epoxide (II) with 3,4-dimethoxybenzylamine gives OPC-18790.
This compound is also obtained by the reductive alkylation of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinone (III) with 3,4-dimethoxybenzaldehyde.
【1】
Sumida, T.; Fujioka, T.; Teramoto, S.; Tominaga, M.; Yabuuchi, Y.; Mori, T.; Hosokawa, T.; Novel positive inotropic agents; synthesis and biological activities of 6-(3-amino-2-hydroxypropoxy)-2(1H)-quinolinone derivatives. J Med Chem 1992, 35, 20, 3607-12. |
【2】
Fujioka, T.; OPC-18790. Drugs Fut 1993, 18, 12, 1114.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
|
10146 |
Epichlorohydrin; 2-(Chloromethyl)oxirane
|
106-89-8 |
C3H5ClO |
详情 | 详情
|
|
13920 |
(3,4-Dimethoxyphenyl)methanamine; 3,4-Dimethoxybenzylamine; Veratrylamine
|
5763-61-1 |
C9H13NO2 |
详情 | 详情
|
|
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(I) |
13913 |
6-Hydroxy-2(1H)-quinolinone
|
|
C9H7NO2 |
详情 |
详情
|
(II) |
13914 |
6-(2-Oxiranylmethoxy)-2(1H)-quinolinone
|
|
C12H11NO3 |
详情 |
详情
|
(III) |
13915 |
6-(3-Amino-2-hydroxypropoxy)-2(1H)-quinolinone
|
|
C12H14N2O3 |
详情 |
详情
|
合成路线5
该中间体在本合成路线中的序号:
(V) Reaction of 3-furancarboxaldehyde (I) with potassium cyanide in the presence of tert-butyldimethylsilyl chloride and ZnI2 gave the O-silylated cyanohydrin (II). Addition of 2(5H)-furanone (III) to the lithium anion of (II), followed by addition of 3,4-dimethoxybenzaldehyde (V) to the intermediate (IV), yielded adduct (VI). Subsequent acid cyclization of (VI) by means of trifluoroacetic acid or methanesulfonic acid provided the tricyclic derivative (VII) as a diastereomeric mixture. Desilylation of (VII) with concomitant cyanide elimination using either tetrabutylammonium fluoride at low temperature or aqueous ammonium fluoride gave rise to ketone (VIII). This was then epimerized to the title compound by treatment with triethylamine in boiling toluene. Alternatively, desilylation of (VII) with tetrabutylammonium fluoride at room temperature provided directly the title diastereoisomer.
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
47247 |
3-Furaldehyde
|
498-60-2 |
C5H4O2 |
详情 | 详情
|
(II) |
47248 |
2-[[tert-butyl(dimethyl)silyl]oxy]-2-(3-furyl)acetonitrile
|
|
C12H19NO2Si |
详情 |
详情
|
(III) |
19267 |
2(5H)-furanone;furan-2(5H)-one;2-Buten-1,4-olide |
497-23-4 |
C4H4O2 |
详情 | 详情
|
(IV) |
47249 |
|
|
C16H22LiNO4Si |
详情 |
详情
|
(V) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(VI) |
47250 |
2-[[tert-butyl(dimethyl)silyl]oxy]-2-[4-[(3,4-dimethoxyphenyl)(hydroxy)methyl]-5-oxotetrahydro-3-furanyl]-2-(3-furyl)acetonitrile
|
|
C25H33NO7Si |
详情 |
详情
|
(VII) |
47251 |
(4S,4aR,7aR,8R)-4-[[tert-butyl(dimethyl)silyl]oxy]-8-(3,4-dimethoxyphenyl)-7-oxo-4,4a,5,7,7a,8-hexahydrofuro[2,3-f][2]benzofuran-4-carbonitrile
|
|
C25H31NO6Si |
详情 |
详情
|
(VIII) |
47252 |
(4R,4aR,7aR,8R)-4-[[tert-butyl(dimethyl)silyl]oxy]-8-(3,4-dimethoxyphenyl)-7-oxo-4,4a,5,7,7a,8-hexahydrofuro[2,3-f][2]benzofuran-4-carbonitrile
|
|
C25H31NO6Si |
详情 |
详情
|
(IX) |
47253 |
(4aR,7aR,8R)-8-(3,4-dimethoxyphenyl)-4a,5,7a,8-tetrahydrofuro[2,3-f][2]benzofuran-4,7-dione
|
|
C18H16O6 |
详情 |
详情
|
合成路线6
该中间体在本合成路线中的序号:
(I) Amino alcohol (III) was prepared from veratraldehyde (I) by addition of cyanotrimethylsilane, followed by borane reduction of the resultant cyanohydrin (II). Reductive condensation of amine (III) with 2,3-dimethoxybenzaldehyde (IV) gave the secondary amine (V). This was cyclized to the tetrahydroisoquinoline (VI) under acidic conditions. Resolution of the racemic (VI) by means of dibenzoyltartaric acid furnished the desired (S)-amine, which was further acylated with Ac2O to yield the chiral amide (VII). Demethylation of (VII) with boron tribromide afforded the tetrahydroxy compound (VIII). Finally, acetamide hydrolysis under acidic conditions yielded the title compound.
【1】
Anan, H.; Tanaka, A.; Tsuzuki, R.; Yokota, M.; Yatsu, T.; Honda, K.; Asano, M.; Fujita, S.; Furuya, T.; Fujikura, T.; Synthesis, resolution, and renal vasodilation activity of novel DA1 agonists: 4-(3,4-Dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline derivatives. Chem Pharm Bull 1991, 39, 11, 2910. |
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(II) |
63099 |
2-(3,4-dimethoxyphenyl)-2-[(trimethylsilyl)oxy]acetonitrile
|
|
C13H19NO3Si |
详情 |
详情
|
(III) |
63100 |
2-amino-1-(3,4-dimethoxyphenyl)-1-ethanol
|
|
C10H15NO3 |
详情 |
详情
|
(IV) |
17615 |
2,3-Dimethoxybenzaldehyde
|
86-51-1 |
C9H10O3 |
详情 | 详情
|
(V) |
63101 |
2-[(2,3-dimethoxybenzyl)amino]-1-(3,4-dimethoxyphenyl)-1-ethanol
|
|
C19H25NO5 |
详情 |
详情
|
(VI) |
63102 |
4-(3,4-dimethoxyphenyl)-7,8-dimethoxy-1,2,3,4-tetrahydroisoquinoline; 4-(3,4-dimethoxyphenyl)-7-methoxy-1,2,3,4-tetrahydro-8-isoquinolinyl methyl ether
|
|
C19H23NO4 |
详情 |
详情
|
(VII) |
63103 |
1-[(4R)-4-(3,4-dimethoxyphenyl)-7,8-dimethoxy-3,4-dihydro-2(1H)-isoquinolinyl]-1-ethanone
|
|
C21H25NO5 |
详情 |
详情
|
(VIII) |
63104 |
1-[(4R)-4-(3,4-dihydroxyphenyl)-7,8-dihydroxy-3,4-dihydro-2(1H)-isoquinolinyl]-1-ethanone
|
|
C17H17NO5 |
详情 |
详情
|
合成路线7
该中间体在本合成路线中的序号:
(I) The bromination of 3,4-dimethoxybenzaldehyde (I) with Br2 in methanol gives the 6-bromo-3,4-dimethoxybenzaldehyde (II), which is regioselectively demethylated with conc. H2SO4 yielding 6-bromo-3-hydroxy-4-methoxybenzaldehyde (III). The reductocondensation of (III) with 2-(4-hydroxyphenyl)ethylamine (IV) by means of NaBH4 in ethanol affords the secondary amine (V), which is formylated with ethyl formate and formic acid in dioxane furnishing the formamide (VI). The oxidative cyclization of (VI) by means of potassium ferricyanide and K2CO3 in toluene/water gives the (+/-)-bromoformylnarwedine (VII), which is protected with propyleneglycol (VIII) and TsOH in hot toluene yielding the ketal (IX). The reduction of the formyl group of (IX) with LiAlH4 in THF affords racemic narwedine (X), which is submitted to a crystallization-induced chiral transformation using a catalytic amount of seed crystals of (-)-narwedine in refluxing ethanol containing TEA, an 80% of (-)-narwedine (XI) is obtained. Finally, this compound is stereoselectively reduced to the target compound by means of L-selectride in THF.
【1】
Kuenburg, B.; et al.; Development of a pilot scale process for the anti-Alzheimer drug (-)-galanthamine using large-scale phenolic oxidative coupling and crystallisation-induced chiral conversion. Org Process Res Dev 1999, 3, 6, 425.
|
【2】
Chaplin, D.A.; et al.; A concise, scaleable synthesis of narwedine. Tetrahedron Lett 1997, 38, 45, 7931.
|
【3】
Czollner, L.; et al.; New kilogram-synthesis of the anti-Alzheimer drug (-)-galanthamine. Tetrahedron Lett 1998, 39, 15, 2087.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(II) |
36481 |
2-bromo-4,5-dimethoxybenzaldehyde
|
5392-10-9 |
C9H9BrO3 |
详情 | 详情
|
(III) |
36482 |
2-bromo-5-hydroxy-4-methoxybenzaldehyde
|
2973-59-3 |
C8H7BrO3 |
详情 | 详情
|
(IV) |
19988 |
4-(2-Aminoethyl)phenol; Tyramine
|
51-67-2 |
C8H11NO |
详情 | 详情
|
(V) |
36483 |
4-bromo-5-[[(4-hydroxyphenethyl)amino]methyl]-2-methoxyphenol
|
|
C16H18BrNO3 |
详情 |
详情
|
(VI) |
36484 |
2-bromo-5-hydroxy-4-methoxybenzyl(4-hydroxyphenethyl)formamide
|
|
C17H18BrNO4 |
详情 |
详情
|
(VII) |
36689 |
1-bromo-3-methoxy-6-oxo-5,6,9,10-tetrahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepine-11(12H)-carbaldehyde
|
|
C17H16BrNO4 |
详情 |
详情
|
(VIII) |
36692 |
1,2-Propanediol; 1,2-Propylene glycol; 1,2-Dihydroxypropane; Monopropylene glycol; (+/-)-1,2-Propanediol; (+/-)-Propylene glycol; Propan-1,2-diol; propylene glycol
|
57-55-6 |
C3H8O2 |
详情 | 详情
|
(IX) |
36690 |
|
|
C20H22BrNO5 |
详情 |
详情
|
(X) |
26837 |
3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-[1]benzofuro[3a,3,2-ef][2]benzazepin-6-one
|
|
C17H19NO3 |
详情 |
详情
|
(XI) |
36691 |
(4aS,8aS)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-[1]benzofuro[3a,3,2-ef][2]benzazepin-6-one
|
|
C17H19NO3 |
详情 |
详情
|
合成路线8
该中间体在本合成路线中的序号:
(I) Condensation of 3,4-dimethoxybenzaldehyde (I) with malonic acid (II) in the presence of ammonium acetate afforded 3-amino-arylpropionic acid (III), which was esterified with MeOH and SOCl2 to give (IV). Finally, condensation with tetrafluorophthalic anhydride (V) in refluxing AcOH provided the target phthalimide.
【1】
Muller, G.W.; Shire, M.G.; Wong, L.M.; Corral, L.G.; Patterson, R.T.; Chen, Y.; Stirling, D.I.; Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett 1998, 8, 19, 2669.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(III) |
18306 |
3-(3,4-dimethoxyphenyl)-beta-alanine
|
|
C11H15NO4 |
详情 |
详情
|
(IV) |
18307 |
methyl 3-amino-3-(3,4-dimethoxyphenyl)propanoate hydrochloride
|
|
C12H18ClNO4 |
详情 |
详情
|
(V) |
18308 |
4,5,6,7-tetrafluoro-2-benzofuran-1,3-dione; Tetrafluorophthalic anhydride
|
652-12-0 |
C8F4O3 |
详情 | 详情
|
合成路线9
该中间体在本合成路线中的序号:
(II) Reductive alkylation of trans-1,2-cyclohexanediamine (I) with veratraldehyde (II) in the presence of NaBH4 afforded the corresponding bis-(benzylamino)cyclohexane derivative (III). This was then alkylated with solanesyl bromide (IV) in THF to furnish the title compound
【1】
Inomata, K.; Takahashi, T.; Inoue, H.; Taniuchi, M.; Yamazaki, H.; Suzuki, M.; Takazawa, T.; Kawamura, K.; Oshida, N.; Ikemoto, H.; Kishie, T. (Nisshin Seifun Group Inc.); Isoprene derivs.. EP 0787716; JP 1997268162 .
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
23788 |
(1S,2S)-2-aminocyclohexylamine; (1S,2S)-1,2-cyclohexanediamine
|
21436-03-3 |
C6H14N2 |
详情 | 详情
|
(II) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(III) |
60503 |
(1R,2R)-N~1~,N~2~-bis(3,4-dimethoxybenzyl)-1,2-cyclohexanediamine; N-(3,4-dimethoxybenzyl)-N-{(1R,2R)-2-[(3,4-dimethoxybenzyl)amino]cyclohexyl}amine
|
|
C24H34N2O4 |
详情 |
详情
|
(IV) |
60504 |
(2E,6E,10E,14E,18E,22E,26E,30E)-1-bromo-3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaene
|
|
C45H73Br |
详情 |
详情
|
合成路线10
该中间体在本合成路线中的序号:
(XII) Protection of 3,4,5-trimethoxybenzaldehyde (IX) with ethylene glycol (X) affords acetal (XI). After lithiation of (XI) by means of butyllithium, addition to veratraldehyde (XII) furnishes carbinol (XIII). Finally, cyclization of hydroxy acetal (XIII) with alkyne (VIII) under acidic conditions provides the title naphthol derivative.
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(VIII) |
57432 |
methyl 6-ethyl-4-oxo-2-octynoate
|
|
C11H16O3 |
详情 |
详情
|
(IX) |
11136 |
3,4,5-Trimethoxybenzaldehyde
|
86-81-7 |
C10H12O4 |
详情 | 详情
|
(X) |
11295 |
Polyethylene glycol;1,2-Ethanediol;Monoethylene glycol; Ethylene glycol |
107-21-1 |
C2H6O2 |
详情 | 详情
|
(XI) |
57434 |
2-(3,4,5-trimethoxyphenyl)-1,3-dioxolane; 4-(1,3-dioxolan-2-yl)-2,6-dimethoxyphenyl methyl ether
|
|
C12H16O5 |
详情 |
详情
|
(XII) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(XIII) |
57435 |
(3,4-dimethoxyphenyl)[6-(1,3-dioxolan-2-yl)-2,3,4-trimethoxyphenyl]methanol
|
|
C21H26O8 |
详情 |
详情
|
合成路线11
该中间体在本合成路线中的序号:
(IV) A different synthetic strategy requires the precursor phthalide derivative (V), which is prepared by two related ways. 3,4,5-Trimethoxybenzoyl chloride (I) is condensed with 2-amino-2-methyl-1-propanol (II), and the resultant hydroxy amide is further cyclized with SOCl2 to the oxazoline (III). Lithiation of (III), followed by addition to veratraldehyde (IV) and acidic oxazoline hydrolysis, leads to the target lactone (V). Alternatively, isobenzofuranone (V) is obtained by direct condensation between trimethoxybenzoic acid (VI) and veratraldehyde (IV) in the presence of polyphosphoric acid.
【1】
Mori, S.; et al.; Convergent synthesis of S-8921, a new potent hypocholesterolemic arylnapththalene lignan analog. Tetrahedron Lett 1999, 40, 6, 1165.
|
【2】
Mori, S.; Takechi, S.; Kida, S. (Shionogi & Co. Ltd.); Process for producing lignan cpd.. EP 0646570; WO 9424087 .
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
13571 |
3,4,5Ttrimethoxybenzoyl chloride
|
4521-61-3 |
C10H11ClO4 |
详情 | 详情
|
(II) |
21513 |
2-amino-2-methyl-1-propanol;Karl Fischer;2-Amino-2-methyl-propan-1-ol;2-amino-2-methyl-1-propanol |
124-68-5 |
C4H11NO |
详情 | 详情
|
(III) |
57442 |
4-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)-2,6-dimethoxyphenyl methyl ether; 4,4-dimethyl-2-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1,3-oxazole
|
|
C14H19NO4 |
详情 |
详情
|
(IV) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(V) |
57443 |
3-(3,4-dimethoxyphenyl)-4,5,6-trimethoxy-2-benzofuran-1(3H)-one
|
|
C19H20O7 |
详情 |
详情
|
(VI) |
32225 |
3,4,5-trimethoxybenzoic acid
|
118-41-2 |
C10H12O5 |
详情 | 详情
|
合成路线12
该中间体在本合成路线中的序号:
(I) Reduction of 3,4-dimethoxybenzaldehyde (I) with NaBH4 provided benzyl alcohol (II). After conversion of (II) to the benzyl chloride (III) using SOCl2, its reaction with PPh3 (IV) in refluxing xylene afforded phosphonium salt (V). Subsequent Wittig reaction of the corresponding ylide with 4,4-(ethylenedioxy)cyclohexanone (VI) produced the benzylidene derivative (VII), which was reduced to benzyl compound (VIII) by catalytic hydrogenation over Pd/C. The ketal protecting group of (VIII) was then removed by acid hydrolysis to yield cyclohexanone (IX). Finally, the target tetrahydroquinazoline was obtained by condensation of (IX) with cyanoguanidine (X) at 180 C.
【1】
Papoulis, A.T.; Queener, S.F.; Rosowsky, A.; Forsch, R.A.; Synthesis and antiparasitic and antitumor activity. J Med Chem 1999, 42, 6, 1007.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(II) |
23603 |
(3,4-dimethoxyphenyl)methanol
|
93-03-8 |
C9H12O3 |
详情 | 详情
|
(III) |
23604 |
4-(chloromethyl)-2-methoxyphenyl methyl ether; 4-(chloromethyl)-1,2-dimethoxybenzene
|
7306-46-9 |
C9H11ClO2 |
详情 | 详情
|
(IV) |
23605 |
trimethylphosphine
|
594-09-2 |
C3H9P |
详情 | 详情
|
(V) |
23606 |
(3,4-dimethoxybenzyl)(trimethyl)phosphonium
|
|
C12H20O2P |
详情 |
详情
|
(VI) |
11377 |
1,4-Dioxaspiro[4.5]decan-8-one
|
4746-97-8 |
C8H12O3 |
详情 | 详情
|
(VII) |
23608 |
8-(3,4-dimethoxybenzylidene)-1,4-dioxaspiro[4.5]decane; 4-(1,4-dioxaspiro[4.5]dec-8-ylidenemethyl)-2-methoxyphenyl methyl ether
|
|
C17H22O4 |
详情 |
详情
|
(VIII) |
23609 |
4-(1,4-dioxaspiro[4.5]dec-8-ylmethyl)-2-methoxyphenyl methyl ether; 8-(3,4-dimethoxybenzyl)-1,4-dioxaspiro[4.5]decane
|
|
C17H24O4 |
详情 |
详情
|
(IX) |
23610 |
4-(3,4-dimethoxybenzyl)cyclohexanone
|
|
C15H20O3 |
详情 |
详情
|
(X) |
23611 |
N-cyanoguanidine
|
461-58-5 |
C2H4N4 |
详情 | 详情
|
合成路线13
该中间体在本合成路线中的序号:
(I) Knoevenagel condensation of 3,4-dimethoxybenzaldehyde (I) with malonic acid produced the cinnamic acid (II), which was further reduced to (III) by catalytic hydrogenation using Pd/C. Conversion of (III) to the corresponding acid chloride (IV), followed by Friedel-Crafts intramolecular cyclization gave the indanone (V). Nitrosation of (V) yielded the oximino derivative (VI), which was subsequently silylated with t-butyldimethylsilyl chloride and imidazole to afford the O-silyl oxime (VII). Reduction of (VII) with borane-dimethyl sulfide complex produced the amino alcohol (VIII). Without isolation, (VIII) was converted to the dipropylamino compound (IX) by reductive alkylation with propionaldehyde and NaBH(OAc)3. Amino alcohol (IX) was finally deoxygenated by means of triethylsilane in the presence of boron trifluoride etherate.
【1】
Haadsma-Svensson, S.R.; Cleek, K.A.; Dinh, D.M.; et al.; Dopamine D3 receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans. J Med Chem 2001, 44, 26, 4716.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(II) |
28568 |
(E)-3-(3,4-dimethoxyphenyl)-2-propenoic acid
|
2316-26-9 |
C11H12O4 |
详情 | 详情
|
(III) |
40182 |
3-(3,4-dimethoxyphenyl)propionic acid
|
2107-70-2 |
C11H14O4 |
详情 | 详情
|
(IV) |
56565 |
3-(3,4-dimethoxyphenyl)propanoyl chloride
|
|
C11H13ClO3 |
详情 |
详情
|
(V) |
13430 |
5,6-Dimethoxy-1-indanone; 2,3-Dihydro-5,6-dimethoxy-1H-inden-1-one
|
2107-69-9 |
C11H12O3 |
详情 | 详情
|
(VI) |
27302 |
5,6-dimethoxy-1H-indene-1,2(3H)-dione 2-oxime
|
|
C11H11NO4 |
详情 |
详情
|
(VII) |
56566 |
5,6-dimethoxy-1H-indene-1,2(3H)-dione 2-{O-[tert-butyl(dimethyl)silyl]oxime}
|
|
C17H25NO4Si |
详情 |
详情
|
(VIII) |
56567 |
2-amino-5,6-dimethoxy-1-indanol
|
|
C11H15NO3 |
详情 |
详情
|
(IX) |
56568 |
2-(dipropylamino)-5,6-dimethoxy-1-indanol
|
|
C17H27NO3 |
详情 |
详情
|
合成路线14
该中间体在本合成路线中的序号:
(I) Condensation of veratraldehyde (I) with malonic acid and ammonium acetate in refluxing EtOH afforded 3-amino-3-(3,4-dimethoxyphenyl)propionic acid (II). The N-phthaloyl group was introduced in (II) by treatment with N-carbethoxyphthalimide (III) in the presence of Na2CO3. The resulting phthalimido acid (IV) was converted to the title amide via activation with carbonyl diimidazole, followed by treatment with ammonium hydroxide.
【1】
Fernandez-Martinez, E.; et al.; Effects of thalidomide and 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanamide on bile duct obstruction-induced cirrhosis in the rat. Drug Dev Res 2001, 54, 4, 209.
|
【2】
Muller, G.W.; Shire, M.G.; Wong, L.M.; Corral, L.G.; Patterson, R.T.; Chen, Y.; Stirling, D.I.; Thalidomide analogs and PDE4 inhibition. Bioorg Med Chem Lett 1998, 8, 19, 2669.
|
【3】
Muller, G.W.; et al.; Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996, 39, 17, 3238.
|
【4】
Muller, G.W. (Celgene Corp.); Ring closure of N-phthaloylglutamines. EP 1004572; EP 1004580; US 5463063; WO 9501348 .
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
|
12963 |
Malonic acid
|
141-82-2 |
C3H4O4 |
详情 | 详情
|
(I) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(II) |
18306 |
3-(3,4-dimethoxyphenyl)-beta-alanine
|
|
C11H15NO4 |
详情 |
详情
|
(III) |
10283 |
ethyl 1,3-dioxo-1,3-dihydro-2H-isoindole-2-carboxylate; N-Carbethoxyphthalimide
|
22509-74-6 |
C11H9NO4 |
详情 | 详情
|
(IV) |
37235 |
3-(3,4-dimethoxyphenyl)-3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)propionic acid
|
|
C19H17NO6 |
详情 |
详情
|
合成路线15
该中间体在本合成路线中的序号:
(I) The intermediate alcohol (VIII) was prepared as shown in Scheme 27060901a:
Aldol condensation of 3,4-dimethoxybenzaldehyde (I) with 3-hydroxyacetophenone (II) in the presence of KOH provided chalcone (III), which was hydrogenated over Pd/C to yield the corresponding diarylpropanone (IV). Subsequent alkylation of the phenolic hydroxyl group of (IV) with tert-butyl bromoacetate (V) using NaH in DMF gave ether (VI). Then, enantioselective reduction of ketone by means of (+)-beta-chlorodiisopinocampheylborane (VII) at -20 C furnished the (R)-alcohol (VIII).
【1】
Yang, W.; Guo, T.; Keenan, T.P.; Laborde, E.; Holt, D.A. (Ariad Pharmaceuticals Inc.); Synthetic derivs. of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains. JP 2000505475; WO 9731898 .
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(II) |
25331 |
3-hydroxyacetophenone; 1-(3-hydroxyphenyl)-1-ethanone
|
121-71-1 |
C8H8O2 |
详情 | 详情
|
(III) |
25332 |
(E)-3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)-2-propen-1-one
|
|
C17H16O4 |
详情 |
详情
|
(IV) |
25341 |
3-(3,4-dimethoxyphenyl)-1-(3-hydroxyphenyl)-1-propanone
|
|
C17H18O4 |
详情 |
详情
|
(V) |
17430 |
2-Bromoacetic acid tert-butyl ester; tert-butyl 2-bromoacetate; tert-Butyl bromoacetate
|
5292-43-3 |
C6H11BrO2 |
详情 | 详情
|
(VI) |
25342 |
tert-butyl 2-[3-[3-(3,4-dimethoxyphenyl)propanoyl]phenoxy]acetate
|
|
C23H28O6 |
详情 |
详情
|
(VII) |
25343 |
chloro[bis[(1S,2R,3S,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]]borane
|
112246-73-8 |
C20H34BCl |
详情 | 详情
|
(VIII) |
25348 |
tert-butyl 2-[3-[(1R)-3-(3,4-dimethoxyphenyl)-1-hydroxypropyl]phenoxy]acetate
|
|
C23H30O6 |
详情 |
详情
|
合成路线16
该中间体在本合成路线中的序号:
(II) The condensation of 4-benzyloxy-2-hydroxy-6-methoxyacetophenone (I) with 3,4-dimethoxybenzaldehyde (II) by means of KOH in ethanol/water gives the chalcone (III), which is cyclized by means of SeO2 in refluxing isoamyl alcohol to yield the benzopyran (IV). The hydrogenolysis of the benzyl group of (IV) with H2 over Pd/C in chloroform affords the 7-hydroxybenzopyran (V), which is condensed with tert-butyl bromoacetate (VII) by means of CaCO3 in DMF to provide the benzopyranyloxy acetate (VIII). Finally, this compound is deprotected by reaction with p-toluenesulfonic acid in refluxing benzene.
【1】
Yoo, M.; Son, M.W.; Kin, I.Y.; Kin, W.B.; Kin, S.H.; Lee, S.D.; Lim, G.J.; Lim, J.I.; Ahn, B.O.; Baik, N.G.; Kin, D.S.; Oh, T.Y.; Ryu, B.K.; Yang, J.S.; Shin, H.C. (Dong-A Pharmaceutical Co., Ltd.); Gastroprotective flavone/flavone cpds. with therapeutic effect on inflammatory bowel disease. JP 1999514015; US 6025387; WO 9804541 . |
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
27802 |
1-[4-(benzyloxy)-2-hydroxy-6-methoxyphenyl]-1-ethanone
|
|
C16H16O4 |
详情 |
详情
|
(II) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(III) |
27803 |
(E)-1-[4-(benzyloxy)-2-hydroxy-6-methoxyphenyl]-3-(3,4-dimethoxyphenyl)-2-propen-1-one
|
|
C25H24O6 |
详情 |
详情
|
(IV) |
27804 |
7-(benzyloxy)-2-(3,4-dimethoxyphenyl)-5-methoxy-4H-chromen-4-one
|
|
C25H22O6 |
详情 |
详情
|
(V) |
27805 |
2-(3,4-dimethoxyphenyl)-7-hydroxy-5-methoxy-4H-chromen-4-one
|
|
C18H16O6 |
详情 |
详情
|
(VI) |
17430 |
2-Bromoacetic acid tert-butyl ester; tert-butyl 2-bromoacetate; tert-Butyl bromoacetate
|
5292-43-3 |
C6H11BrO2 |
详情 | 详情
|
(VII) |
27806 |
tert-butyl 2-[[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxo-4H-chromen-7-yl]oxy]acetate
|
|
C24H26O8 |
详情 |
详情
|
合成路线17
该中间体在本合成路线中的序号:
(I) The bromination of 3,4-dimethoxybenzaldehyde (I) with Br2 in acetic acid gives 2-bromo-4,5-dimethoxybenzaldehyde (II), which is selectively demethylated with H2SO4 yielding 2-bromo-5-hydroxy-4-methoxybenzaldehyde (III). The reductocondensation of (III) with 2-(4-hydroxyphenyl)ethylamine (IV) by means of NaBH4 affords the secondary amine (V), which is formylated with ethyl formate in dioxane/DMF giving the formamide (VI). The cyclization of (VI) by means of potassium hexacyanoferrate (III) and K2CO3 in hot toluene yields racemic N-formylbromonarwedine (+/-)(VII), which is reduced with lithium tri-tert-butoxyaluminum hydride furnishing a mixture of N-demethylbromogalanhamine (+/-)(VIII) and N-demethylepibromogalanthamine (+/-)(IX). After chromatographic separation of the two racemic epimers, resolution of racemic (+/-)(VIII) is carried out employing di-p-toluoyl tartaric acid to afford the required levo isomer. Alkylation of (-)(VIII) with 1-(3-chloropropyl)piperidine (X) gives (XI), which is finally converted to the title compound by reductive debromination in the presence of Zn and CaCl2.
【1】
Kuenburg, B.; et al.; Development of a pilot scale process for the anti-Alzheimer drug (-)-galanthamine using large-scale phenolic oxidative coupling and crystallisation-induced chiral conversion. Org Process Res Dev 1999, 3, 6, 425.
|
【2】
Kuenburg, B.; Frohlich, J.; Jordis, U.; Czollner, L. (Sanochemia Pharmazeutika AG); New benzazepine derivs., medicaments containing the same and their use to prepare medicaments. WO 9740049 .
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(II) |
36481 |
2-bromo-4,5-dimethoxybenzaldehyde
|
5392-10-9 |
C9H9BrO3 |
详情 | 详情
|
(III) |
36482 |
2-bromo-5-hydroxy-4-methoxybenzaldehyde
|
2973-59-3 |
C8H7BrO3 |
详情 | 详情
|
(IV) |
19988 |
4-(2-Aminoethyl)phenol; Tyramine
|
51-67-2 |
C8H11NO |
详情 | 详情
|
(V) |
36483 |
4-bromo-5-[[(4-hydroxyphenethyl)amino]methyl]-2-methoxyphenol
|
|
C16H18BrNO3 |
详情 |
详情
|
(VI) |
36484 |
2-bromo-5-hydroxy-4-methoxybenzyl(4-hydroxyphenethyl)formamide
|
|
C17H18BrNO4 |
详情 |
详情
|
(VII) |
36485 |
1-bromo-3-methoxy-6-oxo-3a,5,6,9,10,12b-hexahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepine-11(12H)-carbaldehyde
|
|
C17H18BrNO4 |
详情 |
详情
|
(VIII) |
36486 |
(4aS,6R,8aS)-1-bromo-3-methoxy-5,6,9,10,11,12-hexahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-6-ol
|
|
C16H18BrNO3 |
详情 |
详情
|
(IX) |
36487 |
(4aS,6S,8aS)-1-bromo-3-methoxy-5,6,9,10,11,12-hexahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-6-ol
|
|
C16H18BrNO3 |
详情 |
详情
|
(X) |
36488 |
1-(3-chloropropyl)piperidine
|
5472-49-1 |
C8H16ClN |
详情 | 详情
|
(XI) |
36489 |
(4aS,6R,8aS)-1-bromo-3-methoxy-11-[3-(1-piperidinyl)propyl]-5,6,9,10,11,12-hexahydro-4aH-[1]benzofuro[3a,3,2-ef][2]benzazepin-6-ol
|
|
C24H33BrN2O3 |
详情 |
详情
|
合成路线18
该中间体在本合成路线中的序号:
(II) Condensation of 3,4-dimethoxybenzylamine (I) with 3,4-dimethoxybenzaldehyde (II) afforded imine (III), that was subsequently reduced to amine (IV) by means of NaBH4. Reaction of (V) with 2,4,6,8-tetrachloropyridopyrimidine (V) in THF at room temperature produced the 4,8-diamino derivative (VI). The remaining 2- and 6-chloro groups of (VI) were then displaced by aminoalcohol (VII) in boiling THF to furnish adduct (VIII). Finally, selective cleavage of two dimethoxybenzyl groups using trifluoroacetic acid gave rise to the title compound.
【1】
Barlow, H.C.; et al.; Resistance-modifying agents. Part 7: 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of alpha1-acid glycoprotein (AGP). Bioorg Med Chem Lett 2000, 10, 6, 585.
|
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(I) |
13920 |
(3,4-Dimethoxyphenyl)methanamine; 3,4-Dimethoxybenzylamine; Veratrylamine
|
5763-61-1 |
C9H13NO2 |
详情 | 详情
|
(II) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(III) |
41393 |
(3,4-dimethoxyphenyl)-N-[(E)-(3,4-dimethoxyphenyl)methylidene]methanamine; N-(3,4-dimethoxybenzyl)-N-[(E)-(3,4-dimethoxyphenyl)methylidene]amine
|
|
C18H21NO4 |
详情 |
详情
|
(IV) |
41394 |
N-(3,4-dimethoxybenzyl)(3,4-dimethoxyphenyl)methanamine; N,N-bis(3,4-dimethoxybenzyl)amine
|
|
C18H23NO4 |
详情 |
详情
|
(V) |
36173 |
2,4,6,8-tetrachloropyrimido[5,4-d]pyrimidine
|
|
C6Cl4N4 |
详情 |
详情
|
(VI) |
41395 |
N-[8-[bis(3,4-dimethoxybenzyl)amino]-2,6-dichloropyrimido[5,4-d]pyrimidin-4-yl]-N,N-bis(3,4-dimethoxybenzyl)amine; 2,6-dichloro-N(4),N(4),N(8),N(8)-tetrakis(3,4-dimethoxybenzyl)pyrimido[5,4-d]pyrimidine-4,8-diamine
|
|
C42H44Cl2N6O8 |
详情 |
详情
|
(VII) |
41397 |
1-amino-2-propanol
|
78-96-6 |
C3H9NO |
详情 | 详情
|
(VIII) |
41396 |
1-([4,8-bis[bis(3,4-dimethoxybenzyl)amino]-6-[(2-hydroxypropyl)amino]pyrimido[5,4-d]pyrimidin-2-yl]amino)-2-propanol
|
|
C48H60N8O10 |
详情 |
详情
|
合成路线19
该中间体在本合成路线中的序号:
(XXI) Compound (XIII) can be obtained by reductocondensation of 3-chloro-4-fluoroaniline (XIX) with 3,4-dimethoxybenzaldehyde (XXI) using NaCNBH3 or NaBH(OAc)3 in AcOH/i-PrOH to yield the benzylaniline derivative (XXII), which by condensation with 4-chloro-7-fluoro-6-nitroquinazoline (XVIII) in i-PrOH gives the tertiary amine (XXIII) . Substitution of fluoroquinazoline (XXIII) with NaOMe in refluxing MeOH affords the 7-methoxyquinazoline derivative (XXIV), which is reduced to the quinazoline-4,6-diamine (XXV) by means of H2 over Raney Ni in THF. Finally, compound (XXV) is coupled with 4-(piperidin-1-yl)-2-butenoyl chloride (IV) in DMA .
4-(Piperidin-1-yl)-2-butenoyl chloride (IV) can be prepared by condensation of methyl 4-bromocrotonate (XI) with piperidine (X) to yield methyl 4-(piperidin-1-yl)-2-butenoate (XXVI), which is then hydrolyzed with HCl to give 4-(piperidin-1-yl)-2-butenoic acid (XXVII). Finally, acid (XXVII) is reacted with (COCl)2 in the presence of DMF in CH2Cl2 .
【1】
Fakhoury, S.A., Lee, H.T., Reed, J.E., Schlosser, K.M., Sexton, K.E., Tecle, H., Winters, R.T. (Pfizer, Inc.). 4-Phenylamino-quinazolin-6-yl-amides. EP 1746999, JP 200753668, JP 2009007363, US 2005250761, US 7772243, WO 2005107758. |
【2】
Bridges, A.J., Horne, N.M., Jacks, T.E. et al. (Pfizer, Inc.). Preparation of substituted quinazolines. JP 2006517959, US 2004158065, WO 2004069791. |
中间体序号 |
中间体编号 |
品名 |
CAS号 |
分子式 |
供应商 |
用于合成 |
(XXVI) |
68482 |
(E)-methyl 4-(piperidin-1-yl)but-2-enoate |
|
C10H17NO2 |
详情 | 详情
|
(IV) |
68473 |
4-(piperidin-1-yl)-2-butenoyl chloride;(E)-4-(piperidin-1-yl)but-2-enoyl chloride |
|
C9H14ClNO |
详情 | 详情
|
(X) |
10158 |
Piperidine
|
110-89-4 |
C5H11N |
详情 | 详情
|
(XI) |
26358 |
methyl (E)-4-bromo-2-butenoate
|
1117-71-1 |
C5H7BrO2 |
详情 | 详情
|
(XIII) |
68477 |
(E)-N-(4-((3-chloro-4-fluorophenyl)(3,4-dimethoxybenzyl)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide |
|
C33H35ClFN5O4 |
详情 | 详情
|
(XVIII) |
19142 |
4-chloro-7-fluoro-6-nitroquinazoline
|
|
C8H3ClFN3O2 |
详情 |
详情
|
(XIX) |
18688 |
3-Chloro-4-fluorophenylamine; 3-Chloro-4-fluoroaniline
|
367-21-5 |
C6H5ClFN |
详情 | 详情
|
(XXI) |
18304 |
3,4-Dimethoxybenzaldehyde; Veratraldehyde
|
120-14-9 |
C9H10O3 |
详情 | 详情
|
(XXII) |
68478 |
3-chloro-N-(3,4-dimethoxybenzyl)-4-fluoroaniline |
|
C15NClFO2 |
详情 | 详情
|
(XXIII) |
68479 |
N-(3-chloro-4-fluorophenyl)-N-(3,4-dimethoxybenzyl)-6-fluoro-7-nitroquinazolin-4-amine |
|
C23H17ClF2N4O4 |
详情 | 详情
|
(XXIV) |
68480 |
N-(3-chloro-4-fluorophenyl)-N-(3,4-dimethoxybenzyl)-6-methoxy-7-nitroquinazolin-4-amine |
|
C24H20ClFN4O5 |
详情 | 详情
|
(XXV) |
68481 |
N4-(3-chloro-4-fluorophenyl)-N4-(3,4-dimethoxybenzyl)-6-methoxyquinazoline-4,7-diamine |
|
C24H22ClFN4O3 |
详情 | 详情
|
(XXVII) |
26709 |
(E)-4-(1-piperidinyl)-2-butenoic acid;(E)-4-(piperidin-1-yl)but-2-enoic acid |
|
C9H15NO2 |
详情 |
详情
|